Quantcast

Latest Torezolid Stories

2010-11-10 08:30:00

BURLINGTON, Mass., Nov. 10, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the methicillin-resistant Staphylococcus aureus (MRSA) drug market will increase from $631 million in 2009 to $752 million in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The Pharmacor 2010 findings from the topic entitled Methicillin-resistant Staphylococcus aureus (MRSA)...

2010-10-25 15:00:00

SAN DIEGO, Oct. 25 /PRNewswire/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI). The patent...

2010-10-22 15:00:00

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that John Finn, Ph.D., Chief Scientific Officer at Trius Therapeutics, will present "Innovative Antibacterial Drugs by Design; The Trius Therapeutics Story" at the San Diego Biotechnology Network event taking place on October 26, 2010 from 5:30-9:30 p.m. PT. More information on the event is available at http://sdbn.org/october. About Trius Therapeutics Trius Therapeutics is a...

2010-10-06 15:00:00

SAN DIEGO, Oct. 6 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that Karen Joy Shaw, Ph.D., Senior Vice President of Biology at Trius Therapeutics, will present at the 7th Anti-Infectives Partnering and Deal-making Summit taking place in Boston October 7-8, 2010. The presentation, titled "Torezolid: The Second Generation," will take place at 10:50 a.m. ET on October 8. More information on the conference is available at...

2010-10-04 07:00:00

SAN DIEGO, Oct. 4 /PRNewswire/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will participate in a panel discussion on antibiotic drug development at Citi's 5th Annual Biotech Day. The panel titled, How to Kill Superbugs: Novel Antibiotics to Hit Drug Resistant Bacteria, will take place at 2:00 p.m. ET on Tuesday, October 5th at the Westin Waterfront Hotel in Boston. About Trius...

2010-09-13 15:00:00

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as...

2010-09-13 07:00:00

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation to investors attending the Stifel Nicolaus Healthcare Conference on Wednesday, September 15 at 8:35 a.m. ET at the Four Seasons Hotel in Boston, MA. A live webcast will be available through the Investor Relations page of the Trius website at...

2010-06-28 09:26:00

WALTHAM, Mass., June 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of two emerging agents from Forest/AstraZeneca/Takeda and Trius will drive the methicillin-resistant Staphylococcus aureus (MRSA) drug market to increase from $631 million in 2009 to $752 million in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor 2010 findings...

2010-03-29 15:15:00

SAN DIEGO, March 29 /PRNewswire/ -- Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). The trial achieved its primary goal of establishing the safety and tolerability...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.